This year, Congress will consider the third version of The Biosimilar User Fee Act (BsUFA), which will modernize and streamline the biosimilar review process. It is imperative that Congress reauthorize BsUFA. Learn More.
The FTC Must Investigate Pharmacy Benefit Managers!
Pharmacy benefit manager business practices too often deprive patients of lower cost biosimilar options and can, in fact, increase costs. Read our letter urging the FTC to investigate. Learn more.
The Biosimilars Council advocates to increase patient access to lifesaving, affordable biosimilar medicines.
Our members include manufacturers and stakeholders working to develop biosimilar medicines for the U.S. market
Biosimilars approved in the U.S.
Billion in potential savings for patients and payers
Million days of patient therapy where biosimilars were used
Million additional days of patient therapy
The Benefits of Biosimilars
Recent Blogs & Resources
What Patients Are Saying
Expanding access to biosimilars has proven successful in driving down the cost of life-saving therapies.
“Because I have an incurable form of non-Hodgkin lymphoma, I know my medication journey will continue. It is nice to know that when I need a biosimilar again, it will be there for me.”
Helen, 41, Florida
Listen to their stories.
You Can Make A Difference
As the role of biosimilar medicines in our health care system continues to grow, it is essential that patients advocate for affordable biosimilars with their lawmakers. Subscribe to the Biosimilars Bulletin and for alerts on policies that affect your access to these life-saving medicines.